Audio Journal of Cardiovascular Medicine: September 7th 2006

Gilles Montalescot

Freek Verheugt

Angioplasty: Four-Continent RIVIERA Study Identifies “Real World” Modifiable Factors Which Affect Outcome

REFERENCE: Abstract 3413, “Hot Line II” Session, Abstract 649Gilles Montalescot, Pitié-Salpêtriere Hospital, ParisAngioplasty outcomes can be improved by modifying factors identified by the 8000-patient, 23-country, prospective, observational “RIVIERA” study presented at a “Hot Line” session of the cardiology congress in Barcelona.Gilles Montalescotdiscussed the rôle of pre-treatment with clopidogrel, the use of statins, radial rather than femoral access, and the choice of anticoagulation. Peter Goodwin asked him about his findings.

Coagulation Choices in Elective and Primary PCI

REFERENCE: “Hot Line II” SessionFreek Verheugt, Nijmegen University, NetherlandsAmid controversy in Barcelona about the choice of anticoagulation for patients receiving angioplastyFreek Verheugtcommented on the relative merits of low-molecular weight heparin and the factor 10a inhibitor fondaparinux. He gave Peter Goodwin his reactions to recommendations emerging from the RIVIERA study of angioplasty outcome determinants.